Denosumab Discontinuation and the Rebound Phenomenon: A Narrative Review.
Denosumab Discontinuation and the Rebound Phenomenon: A Narrative Review.
复制标题
DOI：
10.3390/jcm10010152
复制
发表时间：
2021-01-04
影响因子：
3.9
通讯作者：
Palermo A
中科院分区：
文献类型：
--
作者：
Anastasilakis AD;Makras P;Yavropoulou MP;Tabacco G;Naciu AM;Palermo A
狄诺塞单抗是一种有效的抗骨吸收剂，只要给药，就能显著增加骨密度并降低所有骨骼部位的骨折率。然而，由于破骨细胞数量和活性的大量增加，其有利的骨骼效应在其停止后迅速逆转，这导致随后的骨转换显著增加超过治疗前值，这种现象通常被描述为“反弹现象”。更重要的是，由于骨吸收的爆发，大多数患者经历快速、严重的骨丢失，这可能导致少数患者发生骨折，特别是多发性椎骨骨折。因此，随后的抗吸收治疗是强制性的，尽管最佳方案尚未明确。在本综述中，我们概述了目前已知的关于地舒单抗停药对骨状态不同方面的负面影响，可能影响它们的因素以及预防它们的策略。
Denosumab is a potent antiresorptive agent that substantially increases bone mineral density and reduces fracture rates at all skeletal sites for as long as it is administered. However, its favorable skeletal effects reverse quickly upon its discontinuation, because of a vast increase of osteoclast number and activity, which leads to a subsequent profound increase of bone turnover above pre-treatment values, a phenomenon commonly described as “rebound phenomenon”. More importantly, most patients experience rapid, profound bone loss due to this burst of bone resorption that may lead in a minority of these patients to occurrence of fractures, especially multiple vertebral fractures. Therefore, subsequent antiresorptive treatment is mandatory, although the optimal regimen is yet to be clarified. In the present review, we outline what is currently known regarding the negative effects of denosumab discontinuation on different aspects of bone status, the factors that may affect them, and strategies to prevent them.
登录
查看更多内容
影响因子：
2.8
作者：
Cavalli L;Brandi ML
通讯作者：
Brandi ML
影响因子：
4.1
作者：
Fassio, A.;Adami, G.;Gatti, D.
通讯作者：
Gatti, D.
影响因子：
2.5
作者：
Anastasilakis, Athanasios D.;Evangelatos, Gerasimos;Iliopoulos, Alexios
通讯作者：
Iliopoulos, Alexios
影响因子：
4.2
作者：
Anastasilakis, Athanasios D.;Polyzos, Stergios A.;Makras, Polyzois
通讯作者：
Makras, Polyzois
影响因子：
6.2
作者：
Anastasilakis, Athanasios D.;Polyzos, Stergios A.;Lamy, Olivier
通讯作者：
Lamy, Olivier